News

Mesoblast's Ryoncil generated $115M in first-year revenue following FDA approval for pediatric SR-aGvHD, with Q4 reaching $36M.

Wave Life Sciences advances WVE-007 to Phase 2a for obesity, targeting BMI 35–50 with comprehensive endpoints including body composition...

FDA approves Pluvicto for metastatic hormone-sensitive prostate cancer, reducing progression or death risk by 33% when added to standard...

Co-Diagnostics raises capital through warrant inducement agreement while awaiting FDA clearance for its first diagnostic platform.

Keros receives $20M milestone as elritercept Phase 3 trial enrolls first patient in MDS study with demanding transfusion independence...

FibroBiologics doses first patients in CYWC628 Phase 1/2 trial for diabetic foot ulcers, targeting interim data by year-end 2026.

Moleculin Biotech updates Annamycin data from its MIRACLE trial in relapsed AML, pricing stock offering at $0.75 per share.

Karyopharm's selinexor misses primary endpoint in Phase 3 endometrial cancer trial despite showing 5.32-month PFS improvement over placebo.

EU authorizes Pfizer-BioNTech XFG COVID-19 vaccine for 2026-2027 with cross-reactive immunity data across multiple JN.1 lineage variants.

Selinexor Phase 3 Trial missed its primary endpoint in endometrial cancer despite a 5.3-month PFS improvement, with p-value falling...